Payment overview · 2025
General Payments
$563.86
39 reported records · 9 companies
Healthcare provider profile · identity verified
Timothy C. Spears, DO
Allopathic & Osteopathic Physicians|Family Medicine · IOLA, KS · NPI 1639173156
Verified facts
What the public records show
CMS Open Payments records show Timothy C. Spears, DO received $563.86 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $180.73 | 32.0% | 20 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $143.30 | 25.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $76.57 | 13.6% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $53.31 | 9.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $33.17 | 5.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.52 | 4.2% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $20.45 | 3.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.58 | 3.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.23 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $563.86 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $177.25 | 19 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $143.30 | 7 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $53.31 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $3.48 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $3.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 414 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 368 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 42 |
| Gabapentin | Gabapentin | 279 | 43 |
| Omeprazole | Omeprazole | 222 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 37 |
| Potassium Chloride | Potassium Chloride | 184 | 35 |
| Furosemide | Furosemide | 163 | 32 |
| Pregabalin | Pregabalin | 157 | 21 |
| Alprazolam | Alprazolam | 155 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 151 | 30 |
| Prednisone | Prednisone | 149 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 30 |
| Trazodone Hcl | Trazodone Hcl | 141 | 19 |
| Lisinopril | Lisinopril | 139 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 29 |
| Losartan Potassium | Losartan Potassium | 114 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 26 |
| Buspirone Hcl | Buspirone Hcl | 113 | 19 |
| Famotidine | Famotidine | 105 | 17 |
| Sertraline Hcl | Sertraline Hcl | 98 | 15 |
| Celecoxib | Celecoxib | 96 | 19 |
| Metformin Hcl | Metformin Hcl | 91 | 18 |
| Montelukast Sodium | Montelukast Sodium | 91 | 12 |
| Alendronate Sodium | Alendronate Sodium | 89 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 18 |
| Carvedilol | Carvedilol | 80 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 18 |
| Lansoprazole | Lansoprazole | 74 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 73 | 44 |
| Aripiprazole | Aripiprazole | 73 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | suppressed |
| Simvastatin | Simvastatin | 72 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 18 |
| Lorazepam | Lorazepam | 67 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 13 |
| Azithromycin | Azithromycin | 66 | 53 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 64 | suppressed |
| Allopurinol | Allopurinol | 63 | 11 |
| Doxepin Hcl | Doxepin Hcl | 62 | suppressed |
| Meloxicam | Meloxicam | 61 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 60 | 14 |
| Myrbetriq | Mirabegron | 59 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 58 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 30 |
| Ozempic | Semaglutide | 54 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Primidone | Primidone | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 40 |
| Eliquis | Apixaban | 52 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 13 |
| Baclofen | Baclofen | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Fentanyl | Fentanyl | 40 | suppressed |
| Vraylar | Cariprazine Hcl | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 21 |
| Colestipol Hcl | Colestipol Hcl | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 22 |
| Naproxen | Naproxen | 29 | suppressed |
| Nystatin | Nystatin | 29 | 16 |
| Sucralfate | Sucralfate | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 13 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 14 |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | suppressed |
| Etodolac | Etodolac | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 13 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Dexamethasone | Dexamethasone | 18 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $563.86 · 39 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, FARXIGA, GEMTESA, JOURNAVX, PURAPLY WOUND MATRIX, QULIPTA, TRINTELLIX, UBRELVY, VRAYLAR, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error